Compare 3M Company (MMM) vs Summit Therapeutics Inc (SMMT) Price & Performance

MMM trades at $167.52, down 0.62% on the day, with a bearish technical signal but strong fundamentals including a net income margin of 11.9% and consistent earnings beats. Recent news highlights strength in transportation and electronics segments, though consumer demand remains soft. The stock has gained 9.1% over the past year, supported by industrial momentum and cost management initiatives.

Outlook is mixed: analyst consensus is a Buy with a $173 price target, but high debt and valuation ratios pose risks. Near-term catalysts include Q3 2026 earnings and continued segment growth, while headwinds include cost pressures and weak consumer sales. The dividend of $0.78 per share provides income support.

Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.

The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.